63.40 0.00 (0.00%)
After hours: 4:51PM EDT
|Bid||63.32 x 1000|
|Ask||63.78 x 1000|
|Day's Range||62.94 - 65.34|
|52 Week Range||24.03 - 74.81|
|Beta (3Y Monthly)||-0.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.23|
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019.
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (TNDM) Brian B Hansen (insider trades) sold 13,031 shares of TNDM on 07/11/2019 at an average price of $70.04 a share. Continue reading...
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM): Tandem Diabetes Care, Inc., a medical device company, designs, develops...
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 in New York at 1:20pm Eastern Time .
NEW YORK , June 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Fourth paragraph, fourth sentence of release dated June 9, 2019, should read: Time spent below 70 mg/dL was 1.4 percent with Control-IQ technology compared to 1.9 percent in the control group (p
Tandem Diabetes Care (TNDM) plans to file an application seeking FDA approval for use of its Control-IQ technology in t: slim X2 insulin pumps for patients aged 14 and above.
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)First automated insulin delivery pumpTandem Diabetes Care’s (TNDM) automated insulin delivery system, t: slim X2 Insulin Pump with Basal-IQ technology,
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s pump demandIn the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%. The demand rose
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s revenue trajectoryIn its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced positive results from two studies of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology. The t:slim X2 insulin pump with Control-IQ technology utilizes Dexcom G6 continuous glucose monitoring (CGM) sensor values to predict glucose levels and adjust insulin delivery to prevent highs and lows, while still allowing the user to manually bolus for meals.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced that management will hold a conference call on Sunday, June 9, 2019 at 8:00pm Eastern Time following data presentations at the 79th Scientific Sessions of the American Diabetes Association on its t:slim X2 with Control-IQ technology system.
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes is the IBD Stock Of The Day after the medical device company knocked its first-quarter results out of the park this month. Now, Tandem stock is approaching a breakout.
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced that management will present a Company update at the followin